Patient Capital: The Case for Money with Stamina

In the late 2000s we identified a private bank as a potential turnaround. Its financials were troubled. Cost-to-income was high relative to peers. Productivity per employee lagged compared to other private banks. Yet the strategic context was compelling. The bank had been incorporated nearly eight decades earlier, and through a series of transactions, a large global financial group had become its largest shareholder, holding a 44% stake. That group had identified India and China as focus markets for banking, insurance, and asset management. It followed that the group would play a strong role in the bank's future in India. The addressable market was large and underpenetrated. The missing piece was execution.

We recognised that management changes were underway. Over several months, the organisational structure was reorganised. New professionals were brought in. A Core Banking Solution was implemented. These are not quarterly fixes. They are multi-year repairs to the engine of a bank. During the transition, productivity improved and cost-to-income declined. The market began to re-rate the business. Quarter after quarter, results were still weak. The easy choice was to exit. We held because we could see the slow process of change. In 2015 the bank merged with another Bank. We continued to find the combined entity attractive. The franchise was stronger, the growth runway longer.

The outcome rewarded the waiting. Impatient capital would have sold the dip and missed the re-rating.

The same pattern appears elsewhere. One of the auto company transitioned from a scooter maker to a motorcycle and three-wheeler leader took years. Margins expanded only after scale, distribution, and product mix aligned. The story was obvious in hindsight. It was not obvious quarter to quarter.

Patient capital is money with stamina. Instead of demanding exits on a fixed calendar, it allows the investment theme to be realised. That shift in time horizon changes what gets built and who wins. It buys time for real compounding.

There are many reasons to invest in a company or an asset class. Research may be funded and the outcome is uncertain. Management may be new and culture takes years to reset. The addressable market may be expanding, but penetration is slow. A company may have the right to win in new products, yet distribution must first reach critical mass. Or a business may be in a difficult spot with a credible plan to recover. In each case, the work is real but the payoff is deferred.

Fast capital forces speed. Startups burn cash to hit quarterly growth so the next round of funding looks compelling. That pressure can create fragile companies, big on metrics, thin on moat. Patient capital does the opposite. It lets a company solve hard problems before it scales them. Investing is not about finding next quarter's winner. It is about owning the business that wins over many quarters and builds durable moats along the way.

Public equities tempt us to trade. Liquidity means you can exit anytime. That flexibility is valuable, but it can also destroy returns if it turns into impatience. The advantage of public markets is that you can underwrite a ten-year thesis without lock-ups. You do not need an Initial Public Offering (IPO) or Mergers and Acquisitions(M&A) event to realise value. Price discovery is daily, but value creation is not. Venture and private equity filter for a different mandate: generally ten times in five years, or similar. There is nothing wrong with that. It is simply a different style. The economics, skill set, and risk appetite differ. Fast capital may exit a trough. Patient capital stays on. Fast capital generally chases high Internal Rate of Returns(IRRs) realised quickly. Patient capital may accept lower IRRs for longer duration and potentially higher absolute outcomes.

The trade-off is clear. You will miss ten quick flips. But you get to own the one company that redefines a sector. You also get resilience. Patient-backed firms survive downturns because they were not optimised for the next round. They were optimised for the next decade.

Institutional investors such as pension funds, sovereign funds, endowments, and family offices are natural homes for patient capital. Their liabilities are long dated. Their mandates allow them to ride cycles. For individuals, the same long horizon is possible at the asset-class level. Equities can be held for twenty years. At the single-stock level, however, the horizon should be thesis-dependent. Be patient, not stubborn. Thesis drift is real. The job is to distinguish between a temporary setback and a broken story.

The lesson is not that time alone creates value. Time without execution is just drift. The lesson is that value creation in complex businesses is lumpy and non-linear. Research, regulation, distribution, culture, none of these move in straight lines. If capital is impatient, it forces management to optimise for optics. If capital is patient, it gives management permission to do the hard, unglamorous work that builds moats.

Markets reward patience unevenly. There will be years where fast capital outperforms. There will be cycles where narratives beat numbers. Over the full span, however, compounding accrues to businesses that get better and to owners who let them. Patient capital is restrained in its actions. It monitors closely, but it does not flinch at noise.

Money with stamina does not guarantee success. But it increases the odds that when success arrives, you still own it. That is the entire game. In a world built for speed, the edge may simply be the willingness to wait.

Source: Company disclosures

Not available for investors in US, Canada, EEA, UK, Switzerland, or Australia.

Disclaimer: This article is for information purposes only. It is not a recommendation and should not be treated as such.

• The views expressed herein constitute only the opinion and do not constitute any guidelines or recommendation on any course of action to be followed by the viewer. This is not meant to serve as professional guide.
• Investments in securities market is subject to market risks. Viewers are advised to seek independent professional advise and read the offering documents carefully before making any investment decision.
• Quantum Advisors Private Limited (QAPL), a SEBI registered Portfolio Manager and Quantum Information Services Private Limited (QIS), a SEBI registered Research Analyst are affiliated entities. These entities are functionally and operationally independent of each other and are governed by their respective regulations.
• QAPL has its own inhouse research and investment team for all its strategy offerings. QAPL seeks "Research Inputs" or "Research Services" of non-binding nature from QIS with respect to mutual funds and equity stocks and also marketing and promotion services for one of its strategy offerings viz., Quantum OCIO Strategy. Towards these services, QAPL pays QIS a composite compensation that is linked to the management / advisory fees earned by Quantum Advisors from the assets managed or advised under the OCIO strategy, and the same is paid out of the management / advisory fees that QAPL receives from its clients under the OCIO Strategy.
• Please note that the stock/sector mentioned in the article is for understanding purpose only and should not be construed as an investment advice for buy or sell in any sector/stock. The stock/sector may or may not form part of the portfolio. The historical results are not indictive of future results.